MyMatrixx IDs 3 Drugs of Interest to Comp Industry

Pharmacy benefit management firm myMatrixx identified three drugs currently being developed that are of potential interest to the workers’ compensation community, including an overdose antidote for fentanyl and medications to treat COVID-19. The first drug, nalmefene, is an opioid overdose antidote originally approved by the Food and Drug Administration in 1995 and subsequently taken off the market because of low sales. There is renewed interest in the drug that could have advantages over naloxone, including a longer half-life and quicker onset time. “It remains to be seen if any...